The SmartCTP™ utilizes customizable, intelligent platform technology specifically designed to monitor the patient's symptoms and vitals in real-time. The goals are to manage potential medication toxicity and improve the patient care.
HOUSTON (PRWEB) January 25, 2018
Witty Health Inc., a digital therapeutic-pharmaceutical company, announces the appointment of Karthik Koduru, MD to its Board of Directors and the initiation of clinical development of its Smart Cancer Treatment Platform (SmartCTP™) for use during cancer treatment.
"We are excited to have Dr. Karthik Koduru join our Board at this critical time as we have completed the clinical protocol for a randomized clinical study and identified three investigative centers," said Witty Health co-founder Ram Sesha. "Dr. Koduru's expertise with innovative medicines in cancer care will enable Witty Health to clinically validate our Smart Cancer Treatment Platform and seek FDA approval as a prescription therapeutic based on clinical evidence. This further enables payer, pharmaceutical, and biotech collaborations. We expect the SmartCTP™ will be integrated in a blockchain based ecosystem for monitoring patients during treatment with any cancer drug."
In his role as a Board Member and Chief Oncologist, Dr. Koduru will oversee the clinical study strategy for Witty Health's SmartCTP™ and pilot the study at major cancer centers to gather data for an FDA New Drug Application as a prescription-only digital therapeutic. Dr. Koduru specializes in multiple oncologic areas including leukemia and lymphoma. He is an experienced oncologist with a commitment to personalized medicine, understanding that the individual needs and response to treatment varies widely among cancer patients.
"The research shows that patients with cancer benefit from 24-hour monitoring," stated Dr. Koduru. "The SmartCTP™ utilizes customizable, intelligent platform technology specifically designed to monitor the patient's symptoms and vitals in real-time. The goals are to manage potential medication toxicity and improve the patient care. Through an engaging partnership with payers, cancer drug marketers, and oncologists, we believe our product can significantly reduce preventable healthcare costs by reducing ER visits and hospitalizations due to symptom exacerbations."
About the Smart Cancer Treatment Platform
Witty Health's Smart Cancer Treatment Platform (SmartCTP™) enables patients to send drug-specific toxicity information and vitals from connected devices to their oncologists remotely. The SmartCTP™ connects with multiple devices including: wireless scales, blood pressure cuffs, pulse oximeters, stethoscopes, thermometer,s multi-scope cameras, ECG, and blood glucose monitors. These tools generate data that can be uploaded remotely to healthcare providers in real-time. This encourages communication between office visits. Monitoring with the SmartCTP™ helps oncologists monitor medication adherence and identify symptom or toxicity issues early for timely intervention, improved treatment outcomes, and an enhanced patient experience.
The SmartCTP™ is protected by a number of novel patent applications covering the treatment with Checkpoint, CDK 4/6 and PARP inhibitors and pain management during cancer therapy. The SmartCTP™ is customizable to five checkpoint inhibitors: Opdivo®, Keytruda®, Imfinzi™, Tecentriq® and Bavencio™; three CDK 4/6 inhibitors: Ibrance®, Abemaciclib, and Kisqali®; PARP inhibitor Lynparza™; and any pain medication.
About Witty Health
Witty Health, Inc. is a Houston-based technology company focusing on intelligence-powered, real-time health risk monitoring solutions to improve cancer care. Witty Health, privately held by employees and outstanding physician/oncology leaders, is redefining cancer treatments through the development and commercialization of its proprietary Cancer Treatment Platform (CTP™). The Company uses the InstaMD platform design which includes: a telemedicine-based remote clinic, home health monitoring, patient diagnosis, and messaging application modules.